ATE495192T1 - Mit voluminösen oder lipophilen gruppen modifizierte cyctotoxische peptide - Google Patents

Mit voluminösen oder lipophilen gruppen modifizierte cyctotoxische peptide

Info

Publication number
ATE495192T1
ATE495192T1 AT99941773T AT99941773T ATE495192T1 AT E495192 T1 ATE495192 T1 AT E495192T1 AT 99941773 T AT99941773 T AT 99941773T AT 99941773 T AT99941773 T AT 99941773T AT E495192 T1 ATE495192 T1 AT E495192T1
Authority
AT
Austria
Prior art keywords
cyctotoxic
voluminous
lipophilic groups
peptides modified
well
Prior art date
Application number
AT99941773T
Other languages
German (de)
English (en)
Inventor
John Svendsen
Yystein Rekdal
Baldur Sveinbjyrnsson
Lars Vorland
Original Assignee
Lytix Biopharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lytix Biopharma As filed Critical Lytix Biopharma As
Application granted granted Critical
Publication of ATE495192T1 publication Critical patent/ATE495192T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
AT99941773T 1998-08-28 1999-08-31 Mit voluminösen oder lipophilen gruppen modifizierte cyctotoxische peptide ATE495192T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9818938.4A GB9818938D0 (en) 1998-08-28 1998-08-28 Bioactive peptides
PCT/GB1999/002850 WO2000012541A2 (en) 1998-08-28 1999-08-31 Cytotoxic peptides modified by bulky or lipophilic moieties

Publications (1)

Publication Number Publication Date
ATE495192T1 true ATE495192T1 (de) 2011-01-15

Family

ID=10838089

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99941773T ATE495192T1 (de) 1998-08-28 1999-08-31 Mit voluminösen oder lipophilen gruppen modifizierte cyctotoxische peptide
AT99941774T ATE513847T1 (de) 1998-08-28 1999-08-31 Bioaktive peptide

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT99941774T ATE513847T1 (de) 1998-08-28 1999-08-31 Bioaktive peptide

Country Status (12)

Country Link
US (3) US6890902B2 (https=)
EP (2) EP1109831B1 (https=)
JP (1) JP5475937B2 (https=)
AT (2) ATE495192T1 (https=)
AU (2) AU772176B2 (https=)
CA (2) CA2341037C (https=)
DE (1) DE69943130D1 (https=)
DK (1) DK1109831T3 (https=)
ES (1) ES2359616T3 (https=)
GB (1) GB9818938D0 (https=)
NO (1) NO333073B1 (https=)
WO (2) WO2000012542A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818938D0 (en) 1998-08-28 1998-10-21 Alpharma As Bioactive peptides
GB0605685D0 (en) * 2006-03-21 2006-05-03 Lytix Biopharma As Inhibition of tumour growth
US8283315B2 (en) 1998-08-28 2012-10-09 Lytix Biopharma As Inhibition of tumour growth
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
GB0005702D0 (en) * 2000-03-09 2000-05-03 Alpharma As Method
GB0005703D0 (en) 2000-03-09 2000-05-03 Alpharma As Compounds
KR20020080731A (ko) * 2001-04-17 2002-10-26 주식회사 이지바이오 시스템 락토페리신 유전자 및 이를 도입한 락토페리신 발현용형질전환체
KR100454595B1 (ko) 2001-11-30 2004-10-28 주식회사 이지바이오 시스템 락토페리신 유전자 및 이를 도입한 형질전환 대장균
SE0200598D0 (sv) * 2002-02-27 2002-02-27 A & Science Invest Ab Pharmaceutical composition and method for treatment or prevention of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences
AU2003239393A1 (en) 2002-05-10 2003-11-11 Agennix Incorporated Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
US7541139B2 (en) * 2002-06-28 2009-06-02 The United States Of America As Represented By The Department Of Health And Human Services Tryptophan as a functional replacement for ADP-ribose-arginine in recombinant proteins
NO20031818D0 (no) * 2003-04-23 2003-04-23 Uni I Tromsoe Fremgangsmåte av bioaktiv peptid forberedelse
WO2005046571A2 (en) * 2003-06-06 2005-05-26 Agennix Incorporated Lactoferrin as an adjuvant in cancer vaccines
KR100773259B1 (ko) 2004-03-19 2007-11-05 모리나가 뉴교 가부시키가이샤 암치료를 위한 약제
CA2571168A1 (en) * 2004-06-17 2006-01-26 Mannkind Corporation Mhc i-binding ssx-241-49 variants
US8034762B2 (en) * 2004-09-02 2011-10-11 Cognosci, Inc. Treatment of subarachnoid hemorrhage with Apo E analogs
WO2006047744A2 (en) * 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
NZ555134A (en) * 2004-11-19 2010-07-30 Fonterra Co Operative Group Methods of immune or haematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer
DE102005051366A1 (de) * 2005-10-25 2007-04-26 Degussa Gmbh Drug Delivery Systeme
WO2007055578A1 (en) * 2005-11-11 2007-05-18 Leids Universitair Medisch Centrum Cyclic antimicrobial peptides derived from lactoferrin
ATE501169T1 (de) 2005-12-30 2011-03-15 Evonik Roehm Gmbh Lactoferrin-peptide, geeignet als in die zelle eindringende peptide
ES2321358B1 (es) * 2006-04-05 2010-03-05 Consejo Susperior De Investigaciones Cientificas Uso de peptidos derivados de la lactoferrina para preparar formulaciones inhibidoras de la enzima conversora de angiotensina i.
JP2009535027A (ja) * 2006-04-27 2009-10-01 シンガポール ヘルス サービシーズ ピーティーイー リミテッド 抗菌ペプチド
AU2007272272B2 (en) 2006-07-10 2012-04-12 Pba3 Biomed Gmbh Antimicrobial peptides
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
EP2754450A1 (en) * 2013-01-11 2014-07-16 Österreichische Akademie der Wissenschaften Lactoferricin derived peptides
GB201401877D0 (en) 2014-02-04 2014-03-19 Univ Tromsoe Peptides
JPWO2016056665A1 (ja) * 2014-10-08 2017-08-10 学校法人慶應義塾 白血球の細胞外トラップ形成の阻害剤
ITUB20153058A1 (it) * 2015-08-11 2017-02-11 Farmagens Health Care S R L Roma ?frammento di lattoferrina per uso come agente antibatterico ed antivirale?
WO2017223098A1 (en) * 2016-06-21 2017-12-28 The Curators Of The University Of Missouri Bis-amino acid based compound and use thereof
US11174288B2 (en) 2016-12-06 2021-11-16 Northeastern University Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria
CA3071836A1 (en) 2017-08-04 2019-02-07 Bioventures, Llc Linear lipopeptide paenipeptins and methods of using the same
US11236138B2 (en) * 2020-01-14 2022-02-01 Renorigin Innovation Institute Co., Ltd. Peptide, method and composition for melanin polymerization and hair darkening
CN115073352A (zh) * 2022-06-28 2022-09-20 吉尔多肽生物制药(大连市)有限公司 一种2,5,7-三叔丁基色氨酸的合成方法
CN119859181B (zh) * 2024-12-19 2025-10-17 合肥工业大学 牛乳铁蛋白多肽及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141581A (en) * 1972-10-08 1992-08-25 Markham Harold A Implants with a cover which resists formation of firm spherical encapsulation
US4476116A (en) * 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5073542A (en) 1989-06-07 1991-12-17 Magainin Sciences Inc. CPF peptide compositions and their use in inhibiting growth of target cells or a virus
DK167813B1 (da) * 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
US5141851A (en) 1990-04-18 1992-08-25 Board Of Regents, The University Of Texas System Isolated farnesyl protein transferase enzyme
JP2818056B2 (ja) * 1990-09-07 1998-10-30 森永乳業株式会社 抗菌性ペプチドおよび抗菌剤
DE69220397T2 (de) * 1991-03-13 1997-10-02 Morinaga Milk Industry Co Ltd Antimikrobielles Peptid und antimikrobieller Wirkstoff
JPH06511234A (ja) * 1991-06-12 1994-12-15 マゲイニン　ファーマス−ティカルズ，インコーポレーテッド Ｃ末端置換を有する生物活性ペプチド組成物および治療法
US5547939A (en) * 1991-06-14 1996-08-20 The Regents Of The University Of California Broad spectrum antimicrobial compounds and methods of use
US5631228A (en) * 1991-11-01 1997-05-20 Periodontix, Inc. Anti-fungal and anti-bacterial histatin-based peptides
US5646119A (en) * 1991-11-01 1997-07-08 Periodontix, Inc. D-amino acid histatin-based peptides as anti-fungal and anti-bacterial agents
EP0629347B1 (en) 1992-01-23 1997-07-02 Morinaga Milk Industry Co., Ltd. Antibacterial agent and treatment of article therewith
AU674525B2 (en) * 1992-06-01 1997-01-02 Magainin Pharmaceuticals, Inc. Biologically active peptides having N-terminal substitutions
JPH07509128A (ja) * 1992-07-13 1995-10-12 バイオネブラスカ・インコーポレーテッド 組換型ポリペプチドの修飾方法
US5593866A (en) 1992-08-21 1997-01-14 The University Of British Columbia Cationic peptides and method for production
AU5743194A (en) 1992-12-03 1994-06-22 Magainin Pharmaceuticals, Inc. Treatment of dermatological malignancies with biologically active peptides
JP3312946B2 (ja) * 1993-03-04 2002-08-12 雪印乳業株式会社 ウイルス感染・増殖抑制剤
US5789542A (en) * 1994-04-22 1998-08-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Amphipathic peptides
WO1998006425A1 (en) * 1996-08-12 1998-02-19 A+ Science Invest Ab Treatment and prevention of infections, inflammations and/or tumours with lactoferrin and/or lactoferricin
KR20000029948A (ko) * 1996-08-14 2000-05-25 한스 루돌프 하우스;헨리테 브룬너;베아트리체 귄터 식물병원성진균에대해억제활성을갖는펩타이드
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
WO1998040091A1 (en) * 1997-03-13 1998-09-17 The Research Foundation Of State University Of New York Microbicidal peptides and methods of use
GB9818938D0 (en) 1998-08-28 1998-10-21 Alpharma As Bioactive peptides

Also Published As

Publication number Publication date
DK1109831T3 (da) 2011-04-18
US7439228B2 (en) 2008-10-21
US6890902B2 (en) 2005-05-10
CA2341037A1 (en) 2000-03-09
JP2002523517A (ja) 2002-07-30
NO20010995D0 (no) 2001-02-27
ATE513847T1 (de) 2011-07-15
AU5526899A (en) 2000-03-21
JP5475937B2 (ja) 2014-04-16
ES2359616T3 (es) 2011-05-25
WO2000012541A2 (en) 2000-03-09
DE69943130D1 (de) 2011-02-24
AU772176B2 (en) 2004-04-08
US20030148936A1 (en) 2003-08-07
AU5526799A (en) 2000-03-21
US20030022821A1 (en) 2003-01-30
EP1109831A2 (en) 2001-06-27
CA2340326A1 (en) 2000-03-09
GB9818938D0 (en) 1998-10-21
EP1109831B1 (en) 2011-01-12
WO2000012542A3 (en) 2000-06-29
CA2341037C (en) 2013-11-05
NO333073B1 (no) 2013-02-25
WO2000012542A2 (en) 2000-03-09
NO20010995L (no) 2001-04-27
EP1109827B1 (en) 2011-06-22
WO2000012541A3 (en) 2000-06-08
US20080287346A1 (en) 2008-11-20
EP1109827A2 (en) 2001-06-27
US8143211B2 (en) 2012-03-27

Similar Documents

Publication Publication Date Title
ATE495192T1 (de) Mit voluminösen oder lipophilen gruppen modifizierte cyctotoxische peptide
NO923142L (no) Cykliske peptider og anvendelse derav
EP0696208A4 (en) ORAL DELIVERY FORM AND METHOD
BR9807076B1 (pt) "uso de acetato de glatirâmero para a fabricação de medicamento para o tratamento de esclerose múltipla e composição farmacêutica"
IL127352A (en) Pyridyl alkene- and pyridyl alkine-acid amides and pharmaceutical compositions containing them
FI905956A0 (fi) Foerfarande foer producering av ett biologiskt aktivt protein.
MY121908A (en) 3-amidopyrazole derivatives, process for preparing these and pharmaceutical compositions containing them.
HUP0100928A2 (hu) Humán inzulin B láncának részletét tartalmazó peptidanalógok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
ATE165100T1 (de) Peptide mit endothelin antagonistischer aktivität, deren herstellung und pharmazeutische zusammensetzungen
ATE210988T1 (de) Zytotoxischer aminozucker und verwandte zuckerderivate von indolopyrrolocarbazolen
AR013079A1 (es) Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
DE69900756D1 (de) Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung
FR2647677B1 (fr) Nouvelles micro-proteines, procede de preparation et application a titre de medicaments de ces nouvelles micro-proteines
DE60117247D1 (de) Phosphoramidat-prodrugs
ES2133295T3 (es) Peptidos ciclicos y su uso.
MX9302327A (es) Aminoacidos ciclicos novedosos y derivados de los mismos.
MXPA01011955A (es) Aminoacidos policiclicos, fusionados, como agentes farmaceuticos.
YU60199A (sh) Nove soli bpc peptida sa organo-zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena u terapiji
DE69412612D1 (de) Desoxyazaphospholipid-derivate mit inhibierender aktivität auf phospholipase
FR2766489B1 (fr) Derives de streptogramines, leur preparation et les compositions qui les contiennent
AR018328A1 (es) Forma cristalina de la 1s-[1 alfa(2s*,3r*), 9 alfa-]-6,10-dioxo-n-(2-etoxi-5-oxo-tetrahidro-3-furanil)-9-[[(1-isoquinolil)carbonil]amino]octahidro-6-h-piridazino[1,2-a][1,2] diazepina-1-carboxamida, su procedimiento de preparacion , su aplicacion en la preparacion de un medicamento, y las composicio
DE69808287D1 (de) Pharmazeutische zusammensetzungen von cinchonin dihydrochlorid

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1109831

Country of ref document: EP